PMID- 30598687
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2018
DP  - 2018
TI  - JYYS Granule Mitigates Renal Injury in Clinic and in Spontaneously Hypertensive 
      Rats by Inhibiting NF-kappaB Signaling-Mediated Microinflammation.
PG  - 8472963
LID - 10.1155/2018/8472963 [doi]
LID - 8472963
AB  - INTRODUCTION: Hypertensive renal damage is a chronic and life-threatening kidney 
      disease all over the world. The traditional Chinese medicine Jiang Ya Yi Shen 
      (JYYS) granule has been a perfect drug for patients with hypertensive renal 
      injury in clinic for 20 years in China. However, the molecular mechanism of JYYS 
      granule remains unknown in treatment of this disease. METHODS: The clinic data 
      were from this study's patients. The clinical symptoms of patients were indicated 
      by (N-Acetyl-beta-D-Glucosaminidase) NAG, (albumin) Alb, and (beta2-microglobin) beta2-MG 
      content in urinary of patients, and renal artery's hemodynamic parameters 
      including (pulse index) PI, mean velocity of the arterial blood (Vm), minimum 
      velocity of the diastolic stage (Vdmin) and peak velocity of the systolic wave 
      (Vsmax). To further observe the effect of JYYS granule on renal damage, the rats 
      were included in six groups: normal rats (WKY), spontaneously hypertensive rats 
      (SHR), positive drug-treated rats (Benazepril), low dose JYYS (L), middle dose 
      JYYS (M), and high dose JYYS (H). Then, we observed the effect of JYYS on renal 
      function, renal tubules, inflammatory cell infiltration, and small artery 
      thickening, and we explored the potential mechanism of JYYS in treatment of renal 
      injury. RESULTS: JYYS significantly improved the clinic symptoms of patients with 
      hypertensive nephropathy by downregulating NAG, Alb, and beta2-MG content in urinary 
      of patients and by decreasing renal artery's hemodynamic parameters including PI, 
      Vm, Vdmin, and Vsmax. In SHR, JYYS significantly improved renal function 
      including creatinine clearance rate, urinary albumin/creatinine, beta2-MG/creatinine 
      and arteria caudalis pressure in SHR. Secondly, light and electron microscopic 
      examinations told that after administration of JYYS and Benazepril, the mesangial 
      region exhibited no hyperplasia and renal capsule did not expanded, and there no 
      abnormalities were observed in renal tubules, inflammatory cell infiltration and 
      small artery thickening in SHR. Thirdly, JYYS exhibited its protective role by 
      inhibiting nuclear factor kappa beta signaling-mediated micro-inflammation 
      cytokines including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), 
      intercellular cell adhesion molecule-1 (ICAM-1), and monocyte chemotactic protein 
      1 (MCP-1) in SHR. CONCLUSION: JYYS is a promising prescription of Chinese 
      medicine for patients with hypertension and hypertensive renal damage.
FAU - Yan, Dong
AU  - Yan D
AD  - Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of 
      TCM, Nanjing, China.
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Yue, Bowen
AU  - Yue B
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Qian, Muyan
AU  - Qian M
AD  - Nanjing Foreign Language School, Nanjing, China.
FAU - Zhao, Lili
AU  - Zhao L
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Zhang, Zihan
AU  - Zhang Z
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Qian, Hui
AU  - Qian H
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Yan, Shihai
AU  - Yan S
AD  - Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of 
      TCM, Nanjing, China.
FAU - Qian, Yuliang
AU  - Qian Y
AUID- ORCID: 0000-0001-8337-1277
AD  - Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of 
      TCM, Nanjing, China.
AD  - Nanjing University of TCM, Nanjing, China.
FAU - Fang, Zhuyuan
AU  - Fang Z
AUID- ORCID: 0000-0003-1792-6937
AD  - Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of 
      TCM, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20181126
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC6287156
EDAT- 2019/01/02 06:00
MHDA- 2019/01/02 06:01
PMCR- 2018/11/26
CRDT- 2019/01/02 06:00
PHST- 2018/09/14 00:00 [received]
PHST- 2018/10/20 00:00 [revised]
PHST- 2018/10/23 00:00 [accepted]
PHST- 2019/01/02 06:00 [entrez]
PHST- 2019/01/02 06:00 [pubmed]
PHST- 2019/01/02 06:01 [medline]
PHST- 2018/11/26 00:00 [pmc-release]
AID - 10.1155/2018/8472963 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2018 Nov 26;2018:8472963. doi: 
      10.1155/2018/8472963. eCollection 2018.